Mutated TFPI-2 Kunitz Domain Plasmin Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifibrinolytic agents, such as aprotinin, are not highly specific and can cause immunogenic reactions, leading to potential thrombotic complications and toxicity, necessitating a safer and more potent inhibitor of plasmin that is less immunogenic and has reduced anticoagulation activity.
Innovation Solution
Development of polypeptides with specific mutations, such as changing leucine to arginine at position 17 and tyrosine to glutamic acid at position 46 in the Kunitz domain of TFPI-2, which exhibit enhanced affinity and specificity for plasmin inhibition while minimizing anticoagulation activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aprotinin is used as an antifibrinolytic agent, then plasmin inhibition is effective, but immunogenic reactions and thrombotic complications occur
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the Kunitz domain through site-directed mutagenesis. Specific substitutions (L17R, L26R, Y46E) are introduced to alter the protein's properties, reducing immunogenicity while preserving or enhancing plasmin inhibition capability. This directly addresses the contradiction by changing the molecular parameters of the inhibitor.
Solution Approach 2:
The patent creates a humanized version of the inhibitor by copying and modifying the natural Kunitz domain sequence from TFPI-2. Instead of using the bovine-derived aprotinin, a human sequence is copied and optimized through mutagenesis to achieve better compatibility and reduced immunogenicity in human patients, while maintaining the core inhibitory function.
2Reliability
If BPTI is used to inhibit plasmin, then bleeding control is improved, but renal toxicity and immunogenicity increase
Solution Approach 1:
The patent modifies the physical and chemical parameters of the inhibitor by introducing specific amino acid substitutions. The L17R and L26R substitutions change the charge and hydrophobicity characteristics, while Y46E substitution alters the surface properties. These parameter changes reduce immunogenicity and potential toxicity while maintaining the critical plasmin binding capability for bleeding control.
Solution Approach 2:
The patent uses the Kunitz domain of TFPI-2 as an intermediary structure that can mediate plasmin inhibition with better biocompatibility. By using a human-derived sequence as an intermediary between the need for effective plasmin inhibition and the requirement for reduced immunogenicity, the patent creates a bridge solution that avoids the extreme harmful effects of BPTI.
3Reliability
If EACA or tranexamic acid are used, then fibrin binding is prevented, but plasmin remains as a free protease causing side effects
Solution Approach 1:
The patent extracts and isolates the critical inhibitory function from the limitations of existing agents. By focusing on the Kunitz domain's direct plasmin binding capability and removing the kringles that limit EACA and tranexamic acid, the patent creates an agent that directly neutralizes free plasmin protease activity rather than just preventing fibrin binding, thereby eliminating the harmful effects of unbound plasmin.
Data Source
AI summary
Disclosed are methods and compositions relating to plasmin inhibition.